[SAN DIEGO, CA – December 12, 2022] Mindera Health has completed a $20.3 million Series A-3 financing, led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development, to continue its aggressive growth strategy for the company’s groundbreaking precision medicine technology in the dermatology space. The funds will be used to expand the commercialization of Mind.Px™, Mindera’s flagship tool which prospectively predicts patient response to expensive psoriasis biologics, as well as to continue the development of the Mindera Dermal Intelligence™ Platform. This structured data repository contains large amounts of unique clinical and biochemical data that can be analyzed using machine learning methods to reveal previously unknown correlations.
Mind.Px™ is a first-of-its-kind precision medicine dermatology solution that aligns patient, physician, and payor interests. By predicting which biologic drugs will be effective for patients, physicians avoid trial-and-error prescription practices, payors avoid wasted spending, and most importantly, patients avoid unnecessary disease progression. The novel Mindera technology platform uses a simple, external skin patch that extracts over 7,000 biomarkers in minutes. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the patient’s skin at the exact moment of the test. In the case of Mind.Px™, this rich patient-specific data is then analyzed by proprietary machine learning algorithms to predict the appropriate psoriasis biologic drug for a patient prior to therapeutic selection and treatment.
The closing of this financing, with the support of our lead investors, is a significant validation of Mindera Health’s first-in-class technology platform and our initial solution to help patients suffering from psoriasis,” commented George Mahaffey, President and CEO of Mindera Health.
“Mindera Health is an incredibly exciting company focused on bringing about personalized medicine in dermatology with an initial focus on improving the outcomes for patients with psoriasis. We are honored to be part of Mindera Health and passionate about helping tackle one of the most expensive and pressing challenges in the U.S. healthcare system today,” said Joe C. Cook, III, Managing Director at Mountain Group Partners.
About Mindera Health
Mindera Health is a private San Diego-based company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and ISO 13485 certified Laboratory. Find out more at www.minderahealth.com.
About Mountain Group Partners
Founded in 2002, Mountain Group Partners is a Nashville-based venture capital firm that invests in early-stage companies in the life sciences and disruptive technology sectors. The firm brings over 100 years of combined operational experience and has invested in more than 60 companies. www.mtngp.com.
About Scientific Health Development
Scientific Health Development (SHD) is a Dallas-based venture capital firm focused on early-stage investments in innovative medical device and diagnostic companies addressing large unmet needs. Formed in 2006, SHD is motivated to improve patient outcomes and healthcare economics. The firm is actively investing out of its fourth fund. www.shdpartners.com.